It isn't clear how the treatment helps Alzheimer's patients, but it appears to take advantage of antibodies from the plasma donors that combat a protein called amyloid, which clumps in the brains of people with the ailment.

WSJ: Immune-Disorder Drug Shows Promise for Alzheimer's